Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

Participants were children and adolescents (6-17 years) with T1DM.

Why It Was Studied

Dasiglucagon, a next-generation, ready-to-use aqueous glucagon analog formulation, has been developed to treat severe hypoglycemia in individuals with diabetes.

Who Took Part

The abstract describes 42 participants taking part.

The age groups tagged for this paper are children and teenagers, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

The primary comparison was dasiglucagon vs. placebo; glucagon acted as a reference.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Germany, Glucagon, Hypoglycemia, Insulin and Patient Acuity.

Author keywords: double-blind trial, hypoglycemic agent and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 42 participants.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Pediatric diabetes), a journal based in China.

More context: the Glucagon compound page, all human trials.